Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for TNG456 in Glioblastoma. The expected timing is based on the latest available company guidance and may change.
2/27/25- IND cleared, preclinical studies show improved activity. 8/5/25- First patient treated in May 2025, trial enrolling patients. 11/04/25:- FDA granted orphan drug designation for malignant glioma. Initial Ph1/2 safety and efficacy data expected in 2026. 03/05/26:- Initial Ph1/2 monotherapy safety and efficacy data still expected in 2026. 05/13/26:- Initial Ph1/2 TNG456 monotherapy safety and efficacy data in glioblastoma reiterated as key 2026 inflection. 06/08/26:- Initial Ph1/2 glioblastoma data expected H2 2026. 08/11/26:- Initial Ph1/2 data in glioblastoma and other cancers still expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.